Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Healthcare comms network GLOBALHealthPR expands into Asia

Newly-launched Asia-Pacific headquarters will be led by James Yi

- PMLiVE

Albumedix appoints Dr Giles Campion as CMO

He brings experience from Novartis and BioMarin

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

- PMLiVE

GPI appoints commercial director

Alan Stewart joins the life science management consultancy's executive team

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

Shire Basingstoke

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

- PMLiVE

Newron Pharma appoints commercial affairs VP

Dennis Dionne brings expertise from J&J and Novartis

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links